Clinical Trial Update: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 SWOG trial evaluating observation or combination chemotherapy with bortezomib, thalidomide, and rituximab followed by two autologous stem cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Rituxan (rituximab)
• Thalomid (thalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN